NEW YORK (GenomeWeb) – GenomeDx Biosciences announced today that it has signed an exclusive deal with Medison Pharma to distribute its Decipher Prostate Cancer Classifier in Israel and the Palestinian Authority.

Specific terms of the arrangement were not disclosed.

Decipher is a genomic, RNA expression-based test that predicts cancer aggressiveness with an assay of 22 validated biomarkers associated with metastatic disease. Developed by GenomeDx in collaboration with the Mayo Clinic, the test was first launched in the US in 2013.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.